ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2575

Effect of Therapeutic Plasma Exchange on Glomerular Filtration Rate in Patients with Antibody-Mediated Rejection

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical


  • Maza Moreno, Miguel, National Medical Center 20 de Noviembre, Mexico City, Mexico
  • Hernández-Estrada, Sergio, National Medical Center 20 de Noviembre, Mexico City, Mexico
  • Cano, Jose Horacio, National Medical Center 20 de Noviembre, Mexico City, Mexico
  • Diaz Avendaño, Odette Del Carmen, National Medical Center 20 de Noviembre, Mexico City, Mexico
  • Maldonado Tapia, Diana, National Medical Center 20 de Noviembre, Mexico City, Mexico

Group or Team Name

  • Nephrology and Transplant Division

AMR is the main risk factor for graft loss, especially after the first post-transplant year. Up to 80% of patients achieve response with immunosuppressive treatment and TPE, although the response is lower in patients with lateAMR. The objective was to determine the effect of TPEonGFR at 0,1, and 3 months postTPE.


Retrospective study that included patients with a renal transplant of the CMN“November 20”in MexicoCity, from 2016to2019, undergoing membrane TPEforAMR. Analysis was performed using student's t or MannWhitneyU, repeated measures analysis, and Spearman or Pearson test. Significant p was less than 0.05.


25 patients with AMR who received TPE were evaluated. Age:32±11.6 years, 72% from living donor, 52% received Basiliximab. 87% received tacrolimus. 80% of AMR were late. Prevalence of HLAclass II DSA(66%), specifically vs DQandDR (57.2% and 28.8%). There was a significant difference between preTPE GFR and at the end of treatment(p=0.015, r=0.53), and no significant differences between preTPE GFR, with 1or3 monthGFR(p=0.58; p=0.36). When evaluating IFTA or histological score(g+ptc), no difference was detected in the GFR at 1or3 months post-TPE. When comparing the effect of the AMR temporality on the GFR, difference was found at 1and3 months (p=0.022; p=0.01) postTPE, with lower recovery of GFR in patients with early AMR. There was a moderate correlation between GFR at the time of diagnosis of rejection and GFR at 3 months postTPE(r2=0.68,p=0.01), Fig. 1.


Significant difference was demonstrated between the preTPE GFR and immediate postTPE GFR. In our study patients with early AMR presented a poor response to treatment. The GFRupon admission correlated positively with theGFR detected at 3months post-TPE. This suggests a beneficial effect of TPE over GFRfall during the first 3months after diagnosis.